Jazz Pharmaceuticals PLC Form 4 insider transactions

Jazz Pharmaceuticals director Norbert G. Riedel exercised stock options and subsequently sold an equal number of ordinary shares.

Jazz Pharmaceuticals plc's EVP & Chief Financial Officer, Philip L. Johnson, reported the acquisition of 11,857 restricted stock units and additional shares through an employee stock purchase plan.

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, was granted 9,782 restricted stock units, vesting over four years.

Jazz Pharmaceuticals' EVP, Global Head of R&D & CMO, Robert Iannone, was granted 14,822 restricted stock units.

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported the acquisition of shares from RSU vesting and subsequent sales, including for tax obligations.

Jazz Pharmaceuticals plc's President & CEO, Renee D. Gala, was granted 44,465 restricted stock units, aligning executive incentives with long-term company performance.

Jazz Pharmaceuticals plc director Ted W. Love was granted 1,527 restricted stock units, vesting fully on July 24, 2026.

Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena M Patil, exercised stock options and sold a significant number of ordinary shares on February 26, 2026.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, sold 5,343 ordinary shares to cover tax obligations following the vesting of restricted stock units.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, vested 10,116 performance-based ordinary shares on January 16, 2026.

Jazz Pharmaceuticals' SVP, Chief Accounting Officer, Patricia Carr, acquired 2,370 ordinary shares following the vesting of performance-based awards.

Jazz Pharmaceuticals plc's EVP & Chief Legal Officer, Neena M Patil, reported the acquisition of 8,852 ordinary shares from performance awards and the disposition of 3,275 shares for tax obligations.

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, reported the acquisition of shares from performance awards and an employee stock purchase plan, alongside a tax-related disposition.

Jazz Pharmaceuticals plc's EVP, Global Head of R&D & CMO, Robert Iannone, increased his direct beneficial ownership of ordinary shares following the vesting of performance awards and an Employee Stock Purchase Plan acquisition.

Jazz Pharmaceuticals plc's President & CEO, Renee D Gala, reported the vesting of performance share awards and subsequent tax-related share withholding.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd increased his direct beneficial ownership of ordinary shares following the vesting of performance awards and subsequent tax-related share withholding.

Jazz Pharmaceuticals plc Director Patrick G. Enright transferred 5,000 ordinary shares to a former spouse as part of a marital asset division.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, sold 2,238 ordinary shares for a weighted average price of $169.511 per share.

Jazz Pharmaceuticals' President & CEO, Renee D Gala, reported a disposition of 80 ordinary shares for tax purposes and an acquisition of 71 shares via an employee stock plan.

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported exercising stock options and selling ordinary shares on December 5, 2025.

Kenneth W. O'Keefe, a director at Jazz Pharmaceuticals plc, sold 603 ordinary shares to cover tax liabilities from vested restricted stock units.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd exercised stock options and subsequently sold a portion of his ordinary shares on November 26, 2025.

Jazz Pharmaceuticals plc Director Heather McSharry exercised non-qualified stock options and subsequently sold 3,415 ordinary shares.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, sold 1,331 ordinary shares to cover tax liabilities from vested restricted stock units.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd reported the sale of 18,000 ordinary shares and the acquisition of 2,506 restricted stock units.

Jazz Pharmaceuticals' SVP and Chief Accounting Officer, Patricia Carr, reported exercising stock options and selling shares, including those from an employee stock purchase plan.

Jazz Pharmaceuticals plc Director Rick E. Winningham sold 5,500 ordinary shares at $180.8597 per share in a pre-planned transaction.

Jazz Pharmaceuticals' EVP, Global Head of R&D & CMO, Robert Iannone, sold 7,159 ordinary shares for $168.26 each as part of a pre-arranged trading plan.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd sold 5,500 ordinary shares for approximately $730,000 under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals director Bruce C. Cozadd disposed of 15,647 ordinary shares to cover tax obligations related to restricted stock unit vesting.